Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q1 FY27
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Discovery themes featuring this stock
Discovery themes featuring this stock
Emcure Pharmaceuticals Ltd (EMCURE) is currently trading at 2,005.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Emcure Pharmaceuticals is an Indian pharmaceutical company that develops and markets a broad range of pharmaceutical products worldwide, covering major therapeutic areas. It is strongly positioned in acute and chronic segments, such as gynecology, cardiovascular, oncology, and biologics. Emcure has entered into a notable partnership with Novo Nordisk to introduce an exclusive semaglutide drug, a major step in its biotechnology endeavors. This collaboration is expected to drive significant growth and visibility in the innovative drug market. The company reported a strong financial performance for Q3 FY26, with a 20.4% increase in revenue year-over-year and a profit of INR 231 crores, reflecting robust execution of its strategy and growth plans. With an expansive portfolio in both chemistry-driven products and biologics, Emcure focuses heavily on innovation and differentiated product offerings, including biosimilars and specialty products. Emcure's strategic alliances, such as those with Novo Nordisk and Sanofi, highlight its approach to leveraging partnerships to expand its therapeutic reach and enhance its competitive edge in chronic and biotech markets.
Over the past 52 weeks, Emcure Pharmaceuticals Ltd has traded between a low of ₹1,260.10 and a high of ₹2,047.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Emcure Pharmaceuticals Ltd has a market capitalization of approximately 37,498.80. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Emcure Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 36.80 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 37,498.80 Cr, Emcure Pharmaceuticals Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Emcure Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Emcure Pharmaceuticals Ltd is 36.80. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Revenue from operations rose 22.8% year-on-year to about ₹2,580.5 crore, and consolidated net profit rose 36.2% to about ₹292.5 crore for the June 2026 quarter.
Emcure acquired the remaining 12.05% stake in Gennova, taking its holding from 87.95% to 100%.
Bain Capital, via its affiliate BC Investments IV Ltd, sold its remaining roughly 1% stake in Emcure Pharma, completing its exit.
Kotak Mahindra Mutual Fund bought 36 lakh shares, or 1.89% stake, in Emcure Pharmaceuticals via June 9 transactions.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
3537.05 | 44,235 Cr | 38.98 | 9.77 | 0.79 | 23.33 | 29.09 | 18.44 | ||
1976.75 | 37,499 Cr | 36.80 | 7.58 | 0.18 | 18.67 | 21.76 | 10.60 | ||
2181.15 | 35,442 Cr | 85.61 | 7.17 | 0.00 | 5.75 | 7.39 | 4.81 | ||
1585.05 | 33,669 Cr | 93.07 | 13.56 | 0.00 | 14.05 | 18.23 | 9.98 | ||
1845.00 | 30,431 Cr | 105.58 | 23.61 | 0.08 | 19.14 | 22.56 | 12.39 | ||
23430.00 | 30,197 Cr | 60.67 | 16.12 | 0.15 | 19.42 | 23.57 | 16.99 | ||
211.90 | 28,125 Cr | -89.67 | 3.44 | 0.00 | -3.58 | 2.58 | -1.75 | ||
| Median: 7 Co. | — | 1976.75 | 33,669 Cr | 60.67 | 9.77 | 0.08 | 18.67 | 21.76 | 10.60 |
Bearish
7
Neutral
3
Bullish
4
Bearish
7
Neutral
3
Bullish
36
Bearish
0
Neutral
0
Bullish
32
Bearish
7
Neutral
3
Bullish
4
Bearish
7
Neutral
3
Bullish
4
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Emcure Pharmaceuticals is an Indian pharmaceutical company that develops and markets a broad range of pharmaceutical products worldwide, covering major therapeutic areas. It is strongly positioned in acute and chronic segments, such as gynecology, cardiovascular, oncology, and biologics.
Emcure has entered into a notable partnership with Novo Nordisk to introduce an exclusive semaglutide drug, a major step in its biotechnology endeavors. This collaboration is expected to drive significant growth and visibility in the innovative drug market.
The company reported a strong financial performance for Q3 FY26, with a 20.4% increase in revenue year-over-year and a profit of INR 231 crores, reflecting robust execution of its strategy and growth plans.
With an expansive portfolio in both chemistry-driven products and biologics, Emcure focuses heavily on innovation and differentiated product offerings, including biosimilars and specialty products.
Emcure's strategic alliances, such as those with Novo Nordisk and Sanofi, highlight its approach to leveraging partnerships to expand its therapeutic reach and enhance its competitive edge in chronic and biotech markets.
Pharmaceuticals & Biotechnology
Pharmaceuticals
38,042 Cr
Low Risk
37.3
37.4
1.8
7.6
2,047.40
1,260.10
Sales CAGR
Profit CAGR
ROE
ROCE
